HUTCHMED announces preclinical data for HMPL-A251, the first drug candidate utilizing the ATTC technology platform. It features a highly potent PI3K/PIKK inhibitor payload linked to a humanized anti-HER2 IgG1 antibody, showing robust antitumor activity in preclinical studies. HMPL-A251 leverages the synergy between HER2 targeting and PAM pathway inhibition to address resistance against HER2-targeting treatments. In vivo studies demonstrate superior anti-tumor efficacy and tolerability compared to traditional therapies, with low plasma exposure of free payload. Clinical trials for HMPL-A251 are set to begin in late 2025, with multiple ATTC candidates to follow in 2026.

Read more at GlobeNewswire: HUTCHMED Highlights HMPL-A251 Data Presented at the